Compare Cytokinetics Inc (CYTK) vs Exelixis Inc. Common Stock (EXEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Exelixis Inc. Common Stock — how do they compare? Cytokinetics Inc trades at $62.61 (market cap $8.62B), while Exelixis Inc. Common Stock trades at $60.1 (market cap $14.62B). The key difference: Exelixis Inc. Common Stock is the larger of the two by market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Exelixis Inc. Common Stock for 0 Days on average.
| CYTK | EXEL | |
|---|---|---|
Market Cap | $8.62B | $14.62B |
Volume | 2,594,626 | 2,684,957 |
Sector | Health | Health |
52-Week High | $87.26 | $59.13 |
52-Week Low | $54.76 | $34.54 |
Typical Hold Time | 19 Days | 0 Days |
Enterprise Value | $8.72B | $13.95B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.48, up 2.23% today, but faces bearish technical signals with 18 sell indicators versus 4 buy signals. The company shows strong revenue growth potential with recent positive Phase 3 trial results for aficamten in non-obstructive HCM, though it operates at significant losses with a -1,321% net income margin. Cash flow remains heavily dependent on financing activities, with operating cash flow negative at -$555 million in 2026.
Wall Street maintains strong bullish sentiment with 97% buy ratings and a $112.60 consensus price target, representing 80% upside potential. Key risks include continued cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization of pipeline drugs. The stock's valuation appears stretched at 114x sales given current financial performance.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →
